Global Sarcopenia Treatment Market 2022-2028

December 2022 | 60 pages | ID: G072E829989AEN
Gen Consulting Company

Abstracts

The global sarcopenia treatment market is projected to rise by USD 0.9 billion by 2028, according to a new report by Gen Consulting Company. It is anticipated to expand at a CAGR of 4.8 percent during the forecast period.

The report covers market size and growth, segmentation, regional breakdowns, competitive landscape, trends and strategies for global sarcopenia treatment market. It traces the market’s historic and forecast market growth. The report identifies top segments for opportunities and strategies based on market trends and leading competitors’ approaches. This study also provides an analysis of the impact of the COVID-19 crisis on the sarcopenia treatment industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the treatment type, distribution channel, and region. The global market for sarcopenia treatment can be segmented by treatment type: protein supplement, vitamin B12 supplement, vitamin D and calcium supplement, others. Among these, the vitamin D and calcium supplement segment was accounted for the highest revenue generator in 2021. Sarcopenia treatment market is further segmented by distribution channel: hospital, retail, online, others. The retail segment is estimated to account for the largest share of the global sarcopenia treatment market. Based on region, the sarcopenia treatment market is segmented into: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America. North America held the largest share of the global sarcopenia treatment market in 2021 and is anticipated to hold its share during the forecast period.

Market Segmentation

By treatment type: protein supplement, vitamin B12 supplement, vitamin D and calcium supplement, others

By distribution channel: hospital, retail, online, others

By region: North America, Europe, Asia-Pacific, MEA (Middle East and Africa), Latin America

The report has also analysed the competitive landscape of the global sarcopenia treatment market with some of the key players being Bayer AG, Eli Lilly and Company, GSK plc, Nestle SA, Novartis AG, Sanofi S.A., Zydus Lifesciences Limited, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global sarcopenia treatment market.
• To classify and forecast the global sarcopenia treatment market based on treatment type, distribution channel, region.
• To identify drivers and challenges for the global sarcopenia treatment market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global sarcopenia treatment market.
• To identify and analyze the profile of leading players operating in the global sarcopenia treatment market.

Why Choose This Report

• Gain a reliable outlook of the global sarcopenia treatment market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY TREATMENT TYPE

Protein supplement
Vitamin B12 supplement
Vitamin D and calcium supplement
Others

PART 6. MARKET BREAKDOWN BY DISTRIBUTION CHANNEL

Hospital
Retail
Online
Others

PART 7. MARKET BREAKDOWN BY REGION

North America
Europe
Asia-Pacific
MEA (Middle East and Africa)
Latin America

PART 8. KEY COMPANIES

Bayer AG
Eli Lilly and Company
GSK plc
Nestle SA
Novartis AG
Sanofi S.A.
Zydus Lifesciences Limited
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER